HRP20120711T1 - Sublingualna formulacija spreja koja sadrži dihidroartemezinin - Google Patents
Sublingualna formulacija spreja koja sadrži dihidroartemezinin Download PDFInfo
- Publication number
- HRP20120711T1 HRP20120711T1 HRP20120711AT HRP20120711T HRP20120711T1 HR P20120711 T1 HRP20120711 T1 HR P20120711T1 HR P20120711A T HRP20120711A T HR P20120711AT HR P20120711 T HRP20120711 T HR P20120711T HR P20120711 T1 HRP20120711 T1 HR P20120711T1
- Authority
- HR
- Croatia
- Prior art keywords
- composition
- pharmaceutical composition
- use according
- omega
- triglycerides
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 20
- 239000007921 spray Substances 0.000 title claims 2
- BJDCWCLMFKKGEE-HVDUHBCDSA-N Dihydroartemesinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(O)[C@@H]4C BJDCWCLMFKKGEE-HVDUHBCDSA-N 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 229960000981 artemether Drugs 0.000 claims 5
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 claims 5
- 229960002970 artemotil Drugs 0.000 claims 5
- NLYNIRQVMRLPIQ-XQLAAWPRSA-N artemotil Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OCC)O[C@H]4[C@]32OO[C@@]1(C)O4 NLYNIRQVMRLPIQ-XQLAAWPRSA-N 0.000 claims 5
- 229960002521 artenimol Drugs 0.000 claims 5
- BJDCWCLMFKKGEE-ISOSDAIHSA-N artenimol Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-ISOSDAIHSA-N 0.000 claims 5
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 claims 5
- 229960004991 artesunate Drugs 0.000 claims 5
- SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 claims 5
- 239000000945 filler Substances 0.000 claims 5
- 229940057917 medium chain triglycerides Drugs 0.000 claims 5
- 150000003626 triacylglycerols Chemical class 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 4
- 150000007513 acids Chemical class 0.000 claims 4
- DTMGIJFHGGCSLO-FIAQIACWSA-N ethyl (4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoate;ethyl (5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoate Chemical class CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC.CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC DTMGIJFHGGCSLO-FIAQIACWSA-N 0.000 claims 4
- 235000021323 fish oil Nutrition 0.000 claims 4
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010061217 Infestation Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 241000935974 Paralichthys dentatus Species 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 201000005746 Pituitary adenoma Diseases 0.000 claims 1
- 206010061538 Pituitary tumour benign Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000001647 drug administration Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 208000021310 pituitary gland adenoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 239000000341 volatile oil Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Claims (15)
1. Farmaceutska kompozicija za uporabu u liječenju neoplastične bolesti, pri čemu navedena kompozicija sadrži:
artemezinin, artemeter, arteeter, artenimol ili artesunat; i
farmaceutski prihvatljiv inertni punitelj izabran iz grupe koju čine:
trigliceridi srednje dužine lanca;
trigliceridi kratkog lanca;
omega-3-morski trigliceridi; i
riblje ulje, bogato u omega-3-kiselinama
pri čemu je navedena kompozicija formulirana za transmukozalno sublingvalno, bukalno ili nazalno doziranje.
2. Farmaceutska kompozicija za uporabu prema patentnom zahtjevu 1, pri čemu navedena bolest sadrži malignu neoplazmu.
3. Farmaceutska kompozicija za uporabu prema patentnom zahtjevu 2, pri čemu je navedena bolest izabrana iz grupe koju čine:
adenom hipofize;
karcinom skvamoznih stanica;
kancer dojke;
ne-Hočkinov limfom;
kancer kože;
kancer pluća; i
karcinom ne-malih stanica pluća.
4. Farmaceutska kompozicija za uporabu u liječenju infestacije metiljem, pri čemu navedena kompozicija sadrži:
artemezinin, artemeter, arteeter, artenimol ili artesunat; i
farmaceutski prihvatljiv inertni punitelj izabran iz grupe koju čine:
trigliceridi srednje dužine lanca;
trigliceridi kratkog lanca;
omega-3-morski trigliceridi; i
riblje ulje, bogato u omega-3-kiselinama
pri čemu je navedena kompozicija formulirana za transmukozalno sublingvalno, bukalno ili nazalno doziranje.
5. Farmaceutska kompozicija za uporabu u liječenju Lajmske bolesti (borelioze), pri čemu navedena kompozicija sadrži:
artemezinin, artemeter, arteeter, artenimol ili artesunat; i
farmaceutski prihvatljiv inertni punitelj izabran iz grupe koju čine:
trigliceridi srednje dužine lanca;
trigliceridi kratkog lanca;
omega-3-morski trigliceridi; i
riblje ulje, bogato u omega-3-kiselinama
pri čemu je navedena kompozicija formulirana za transmukozalno sublingvalno, bukalno ili nazalno doziranje.
6. Farmaceutska kompozicija za uporabu prema bilo kojem od patentnih zahtjeva 1 do 5, pri čemu se navedena kompozicija sastoji uglavnom od:
artemezinina, artemetera, arteetera, artenimola ili artesunata; i
farmaceutski prihvatljivog inertnog punitelja koji je izabran iz grupe koju čine:
trigliceridi srednje dužine lanca;
trigliceridi kratkog lanca;
omega-3-morski trigliceridi; i
riblje ulje, bogato u omega-3-kiselinama
pri čemu je navedena kompozicija formulirana za transmukozalno sublingvalno, bukalno ili nazalno doziranje.
7. Farmaceutska kompozicija za uporabu prema bilo kojem od patentnih zahtjeva 1 do 5, pri čemu se navedena kompozicija uglavnom sastoji od:
artemezinina, artemetera, arteetera, artenimola ili artesunata; i
farmaceutski prihvatljivog inertnog punitelja koji se uglavnom sastoji od:
triglicerida, koji je tekući na ; i
triglicerida srednje dužine lanca;
pri čemu je navedena kompozicija formulirana za transmukozalno sublingvalno, bukalno ili nazalno doziranje.
8. Farmaceutska kompozicija za uporabu prema bilo kojem prethodnom patentnom zahtjevu, pri čemu je navedena kompozicija značajno bez vode.
9. Farmaceutska kompozicija za uporabu prema bilo kojem prethodnom patentnom zahtjevu, pri čemu je navedena kompozicija značajno bez etanola.
10. Farmaceutska kompozicija za uporabu prema bilo kojem prethodnom patentnom zahtjevu, pri čemu navedena kompozicija dalje sadrži eterično ulje.
11. Farmaceutska kompozicija za uporabu prema bilo kojem prethodnom patentnom zahtjevu, pri čemu je navedena kompozicija formulirana za sublingvalnu primjenu.
12. Farmaceutska kompozicija za uporabu prema bilo kojem prethodnom patentnom zahtjevu, pri čemu je navedena kompozicija sadržana unutar uređaja za primjenu lijeka, pri čemu je navedeni uređaj prilagođen za primjenu pojedinačnih ili uzastopnih doza navedene kompozicije, pri čemu svaka pojedinačna ili uzastopna doza ima volumen od manje od 1000 mikrolitara.
13. Farmaceutska kompozicija za uporabu prema patentnom zahtjevu 12, pri čemu navedeni uređaj sadrži sprej na pumpu.
14. Farmaceutska kompozicija za uporabu prema bilo kojem od patentnih zahtjeva 1 do 11, pri čemu je navedena kompozicija sadržana unutar kontejnera sadržanog unutar uređaja za osiguravanje farmaceutskih doza sa ventilom podešenim da prenosi doze navedene farmaceutske kompozicije u vanjski dio kontejnera.
15. Farmaceutska kompozicija za uporabu prema bilo kojem od patentnih zahtjeva 1 do 11, pri čemu je navedena kompozicija sadržana unutar kompleta koji sadrži uputstva za primjenu navedene kompozicije na pacijenta kod koga postoji potreba za tim preko transmukozalnog sublingvalnog, bukalnog ili nazalnog puta.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0906971.7A GB2469791B (en) | 2009-04-23 | 2009-04-23 | Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of neoplastic disease |
| PCT/GB2009/050415 WO2010122275A1 (en) | 2009-04-23 | 2009-04-23 | Pharmaceutical preparation |
| PCT/GB2010/050672 WO2010122356A1 (en) | 2009-04-23 | 2010-04-23 | Sublingual spray formulation comprising dihydroartemesinin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120711T1 true HRP20120711T1 (hr) | 2012-10-31 |
Family
ID=42244197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120711AT HRP20120711T1 (hr) | 2009-04-23 | 2012-09-06 | Sublingualna formulacija spreja koja sadrži dihidroartemezinin |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US20120157518A1 (hr) |
| EP (1) | EP2424523B1 (hr) |
| JP (1) | JP5795760B2 (hr) |
| CN (1) | CN102395362B (hr) |
| AU (1) | AU2010240654C1 (hr) |
| BR (1) | BRPI1014887A8 (hr) |
| CA (1) | CA2756925A1 (hr) |
| DK (1) | DK2424523T3 (hr) |
| ES (1) | ES2390046T3 (hr) |
| HK (1) | HK1164140A1 (hr) |
| HR (1) | HRP20120711T1 (hr) |
| IL (1) | IL215453A (hr) |
| ME (1) | ME02008B (hr) |
| MX (1) | MX2011010961A (hr) |
| MY (1) | MY155646A (hr) |
| NZ (1) | NZ595469A (hr) |
| PL (1) | PL2424523T3 (hr) |
| PT (1) | PT2424523E (hr) |
| RS (1) | RS52430B (hr) |
| RU (1) | RU2501550C2 (hr) |
| SG (1) | SG175162A1 (hr) |
| SI (1) | SI2424523T1 (hr) |
| WO (1) | WO2010122356A1 (hr) |
| ZA (1) | ZA201107088B (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0720967D0 (en) * | 2007-10-25 | 2007-12-05 | Protophama Ltd | Anti-material pharmaceutical composition |
| SG175160A1 (en) * | 2009-04-23 | 2011-11-28 | Londonpharma Ltd | Sublingual pharmaceutical composition comprising a neutral oil |
| CN105142631A (zh) * | 2013-01-14 | 2015-12-09 | 健康诊所有限公司 | 抗癌药物和用途 |
| WO2016083827A1 (en) | 2014-11-27 | 2016-06-02 | Cipla Limited | Pharmaceutical composition comprising an artemisinin derivative for nasal or pulmonary delivery |
| JP2020033304A (ja) * | 2018-08-30 | 2020-03-05 | 医療法人ふじいやさか | 薬剤又はサプリメント、組成物、及び水素供給器の使用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030082107A1 (en) * | 1997-10-01 | 2003-05-01 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
| CH692321A5 (de) * | 1997-11-03 | 2002-05-15 | Mepha Ag | Pharmazeutisch wirksame Zusammensetzung, welche eine gegen Malariaparasiten wirksame Substanz enthält. |
| IL140402A0 (en) * | 1998-07-14 | 2002-02-10 | Bayer Ag | Antiparasitic artemisinin derivatives (endoperoxides) |
| WO2002053138A2 (en) * | 2001-01-02 | 2002-07-11 | Elisabeth Shanahan-Prendergast | Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens |
| US20060257463A1 (en) * | 2002-05-31 | 2006-11-16 | University Of Mississippi | Transmucosal delivery of cannabinoids |
| AU2003243418B2 (en) * | 2002-06-06 | 2009-02-19 | University Of Washington | Covalent conjugates between artemisinin-related endoperoxides and iron-carrying proteins and methods of use |
| WO2004075921A1 (en) * | 2003-02-26 | 2004-09-10 | Vrije Universiteit Brussel | Inclusion complex of artemisinin or derivates thereof with cyclodextrins |
| US20060084675A1 (en) * | 2004-10-18 | 2006-04-20 | Thomas Efferth | Combined treatment with artesunate and an epidermal growth factor receptor kinase inhibitor |
| US20060233895A1 (en) * | 2005-04-15 | 2006-10-19 | Brown Paul R | Herbal remedy for treating Lyme disease |
| ATE544444T1 (de) * | 2005-10-11 | 2012-02-15 | Yissum Res Dev Co | Zusammensetzungen für die nasale abgabe |
| CN100418524C (zh) * | 2005-10-26 | 2008-09-17 | 重庆医药工业研究院有限责任公司 | 一种稳定的青蒿素及青蒿素衍生物的药物组合物 |
-
2010
- 2010-04-23 ES ES10715337T patent/ES2390046T3/es active Active
- 2010-04-23 EP EP10715337A patent/EP2424523B1/en active Active
- 2010-04-23 NZ NZ595469A patent/NZ595469A/xx not_active IP Right Cessation
- 2010-04-23 JP JP2012506584A patent/JP5795760B2/ja not_active Expired - Fee Related
- 2010-04-23 PL PL10715337T patent/PL2424523T3/pl unknown
- 2010-04-23 SI SI201030076T patent/SI2424523T1/sl unknown
- 2010-04-23 MX MX2011010961A patent/MX2011010961A/es active IP Right Grant
- 2010-04-23 WO PCT/GB2010/050672 patent/WO2010122356A1/en active Application Filing
- 2010-04-23 ME MEP-2012-393A patent/ME02008B/me unknown
- 2010-04-23 RU RU2011139637/15A patent/RU2501550C2/ru active
- 2010-04-23 CN CN201080017965.1A patent/CN102395362B/zh not_active Expired - Fee Related
- 2010-04-23 PT PT10715337T patent/PT2424523E/pt unknown
- 2010-04-23 BR BRPI1014887A patent/BRPI1014887A8/pt not_active Application Discontinuation
- 2010-04-23 SG SG2011073954A patent/SG175162A1/en unknown
- 2010-04-23 RS RS20120393A patent/RS52430B/en unknown
- 2010-04-23 US US13/265,518 patent/US20120157518A1/en not_active Abandoned
- 2010-04-23 DK DK10715337.1T patent/DK2424523T3/da active
- 2010-04-23 MY MYPI2011005080A patent/MY155646A/en unknown
- 2010-04-23 AU AU2010240654A patent/AU2010240654C1/en not_active Ceased
- 2010-04-23 CA CA2756925A patent/CA2756925A1/en not_active Abandoned
-
2011
- 2011-09-28 ZA ZA2011/07088A patent/ZA201107088B/en unknown
- 2011-10-02 IL IL215453A patent/IL215453A/en active IP Right Grant
-
2012
- 2012-05-18 HK HK12104912.3A patent/HK1164140A1/xx not_active IP Right Cessation
- 2012-09-06 HR HRP20120711AT patent/HRP20120711T1/hr unknown
-
2015
- 2015-07-30 US US14/813,424 patent/US20160022629A1/en not_active Abandoned
-
2017
- 2017-09-06 US US15/697,240 patent/US20170368023A1/en not_active Abandoned
-
2018
- 2018-10-18 US US16/164,610 patent/US20190142737A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120711T1 (hr) | Sublingualna formulacija spreja koja sadrži dihidroartemezinin | |
| JP2008044951A5 (hr) | ||
| WO2007134292A3 (en) | Treprostinil administration using a metered dose inhaler | |
| NZ605888A (en) | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain | |
| ES2494340T3 (es) | Composición farmacéutica antipalúdica | |
| WO2011112713A3 (en) | Microneedle nasal delivery device | |
| WO2007012019A3 (en) | Medicaments containing famotidine and ibuprofen and administration of same | |
| EA201390200A1 (ru) | Насосные системы и способы хранения и дозирования множества точно отмеренных стандартных доз крема имиквимода | |
| TW200600117A (en) | Preparation for oral administration | |
| RS54438B1 (en) | PHARMACEUTICAL DOSAGE FORM CONTAINING 6`-FLUORO- (N-METHYL-OR N, N-DIMETHYL) - 4-PHENYL-4`, 9`-DIHYDRO-3`H-SPIRO [CYCLOHEXANE-1,1`-PIRANO [3,4, B] INDOL] -4-AMINE | |
| HRP20210968T1 (hr) | Postupak primjene tekućih analgetika | |
| EA201100984A1 (ru) | Композиции с более низким содержанием имиквимода и короткие режимы дозирования для лечения актинического кератоза | |
| IL196425A0 (en) | Pharmaceutical compositions containing ibuprofen and famotidine | |
| ATE478659T1 (de) | Mehrlagiges arzneimittelausbringsystem mit sperre gegen reservoirmaterialfluss | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| HRP20140592T1 (hr) | Poboljšani medicinski pripravci koji sadrže buprenorfin i naltrekson | |
| HRP20121036T1 (hr) | Intranazalni spojevi | |
| WO2009046369A3 (en) | Use of a specific dosage regimen of ifn-alpha and ribavirin for treating hepatitis c | |
| HRP20200879T1 (hr) | Medicinski aplikator | |
| EP2488168A1 (en) | Combination therapy treatment for viral infections | |
| DE602008006700D1 (hr) | ||
| CR8059A (es) | Composicion farmaceutica en forma de hidrogel para administracion transdermica de sustancias activas | |
| JP2012524772A5 (hr) | ||
| AR028525A1 (es) | Sistema terapeutico transdermal para la administracion de lerisetron | |
| RU2015139515A (ru) | Комбинированное лечение |